Skip to main content
SpringerLink
Log in

Radionuclide Therapy

  • Chapter
Book cover Bone Metastases

Part of the book series: Cancer Metastasis – Biology and Treatment ((CMBT,volume 12))

Abstract

Most patients with advanced cancer develop metastatic bone disease; this untreatable evolution of the disease weights heavily on cancer-related mortality and morbidity. Although bone metastases are often clinically silent, some conditions may support bone pain. Therapeutic strategies for pain palliation could include treatments directed at the source of the pain as well as may focus on comprehensive care of patient. Among the different, mostly palliative, therapies used to treat bone metastases, bone-targeted approaches using bisphosphonates, radiopharmaceuticals, or endothelin receptor antagonists currently hold great promise in terms of efficacy and tolerability. The use of bone-seeking radiopharmaceuticals for pain palliation continues to represent an irreplaceable tool in critical pain conditions. The systemic radionuclide therapy has gained full consideration, with its efficacy being widely accepted. It offers the prospective of pain relief with negligible side effects. Recently, it has been also implemented in combination with other therapeutic modalities. Future considerations for systemic metabolic radiotherapy include its use at an earlier stage in high-risk patients who are likely to develop bone metastases. In addition, this therapy could be implemented in asymptomatic patients with positive bone scans.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Reddi AH, Roodman D, Freeman C, et al. (2003) Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18: 190–194

    PubMed  CAS  Google Scholar 

  2. Nielsen OS, Munro AJ, Tannock IF. (1991) Bone metastases: pathophysiology and management policy. J Clin Oncol 9: 509–524

    PubMed  CAS  Google Scholar 

  3. Coleman RE, Rubens RD. (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55: 61–66

    PubMed  CAS  Google Scholar 

  4. Keller ET, Brown J. (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biol 91: 718–729

    CAS  Google Scholar 

  5. Ribiero M, Ruff P, Falkson G. (1997) Low serum testosterone and a younger age predict poor outcome in metastatic prostate cancer. Am J Clin Oncol 20: 605–608

    Google Scholar 

  6. Posadas EM, Dahut WL, Gulley J. (2004) The emerging role of bisphosphonates in prostate cancer. Am J Ther 11: 60–73

    PubMed  Google Scholar 

  7. Soloway MS, Ishikawa S, van der Waag R, et al. (1989) Prognostic factors in patients with advanced prostate cancer. Urology 33: 53–56

    PubMed  CAS  Google Scholar 

  8. Body JJ. (1992) Bone metastases and tumor-induced hypercalcaemia. Curr Opin Oncol 4: 624–631

    PubMed  CAS  Google Scholar 

  9. Hortobagyi GN. (2002) Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 29: 134–144

    PubMed  CAS  Google Scholar 

  10. Perry CM, Figgitt DP. (2004) Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64: 1197–1211

    PubMed  CAS  Google Scholar 

  11. Marcus CS, Saeed S, Mlikotic A, et al. (2002) Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP. Clin Nucl Med 27: 427–430

    PubMed  Google Scholar 

  12. Lewington VJ. (2005) Bone-seeking radionuclides for therapy. J Nucl Med 46: 38S–47S

    PubMed  CAS  Google Scholar 

  13. Mertens WC. (1993) Radionuclide therapy of bone metastases: prospects for enhancement of therapeutic efficacy. Semin Oncol 20: 49–55

    PubMed  CAS  Google Scholar 

  14. Auclerc G, Antoine EC, Cajfinger F, et al. (2000) Management of advanced prostate cancer. Oncologist 5: 36–44

    PubMed  CAS  Google Scholar 

  15. Lalich M, McNeel DG, Wilding G, et al. (2007) Endothelin receptor antagonists in cancer therapy. Cancer Invest 25: 785–794

    PubMed  CAS  Google Scholar 

  16. Hosain F, Spencer RP. (1992) Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background. Semin Nucl Med 22: 11–16

    PubMed  CAS  Google Scholar 

  17. Serafini AN. (2001) Therapy of metastatic bone pain. J Nucl Med 42: 895–906

    PubMed  CAS  Google Scholar 

  18. Altman GB, Lee CA. (1996) Strontium-89 for treatment of painful bone metastases from prostate cancer. Oncol Nurs Forum 23: 523–527

    PubMed  CAS  Google Scholar 

  19. Uchiyama M, Narita H, Makino M, et al. (1997) Strontium-89 therapy and imaging with bremsstrahlung in bone metastases. Clin Nucl Med 22: 605–609

    PubMed  CAS  Google Scholar 

  20. Baziotis N, Yakoumakis E, Zissimopoulos A, et al. (1998) Strontium-89 in the treatment of bone metastases from breast cancer. Oncology 55: 377–381

    PubMed  CAS  Google Scholar 

  21. Pons F, Herranz R, Garcia A, et al. (1997) Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med 24: 1210–1214

    PubMed  CAS  Google Scholar 

  22. Morris MJ, Scher HI. (2003) Clinical approaches to osseous metastases in prostate cancer. The Oncologist 2: 161–173

    Google Scholar 

  23. Joliot E, Curie I. (1934) Artificial production of a new kind of radioelement. Nature 133: 201–202

    CAS  Google Scholar 

  24. Treadwell AdeG, Low-Beer BVA, Friedell HL, et al. (1942) Metabolic studies on neoplasm of bone with the aid of radioactive strontium. Am J Med Sci 204: 521–530

    Google Scholar 

  25. Pecher C. (1942) Biological investigations with radioactive calciurn and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. University of California Press (ed.) vol 2, Cambridge Press, London

    Google Scholar 

  26. Bouchet LG, Bolch WE, Goddu SM, et al. (2000) Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med 41: 682–687

    PubMed  CAS  Google Scholar 

  27. Ricci S, Boni G, Pastina I, et al. (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 34: 1023–1030

    PubMed  CAS  Google Scholar 

  28. Sciuto R, Festa A, Rea S, et al. (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43: 79–86

    PubMed  CAS  Google Scholar 

  29. Storto G, Klain M, Paone G, et al. (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39: 35–41

    PubMed  CAS  Google Scholar 

  30. Quilty PM, Kirk D, Bolger JJ, et al. (1994) A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31: 33–40

    PubMed  CAS  Google Scholar 

  31. Porter AT, McEwan AJ, Powe JE, et al. (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805–813

    PubMed  CAS  Google Scholar 

  32. Liepe K, Hliscs R, Kropp J, et al. (2000) Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother Radiopharm. 15: 261–265

    PubMed  CAS  Google Scholar 

  33. Dafermou A, Colamussi P, Giganti M, et al. (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28: 788–798

    PubMed  CAS  Google Scholar 

  34. Collins C, Eary JF, Donaldson G, et al. (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34: 1839–1844

    PubMed  CAS  Google Scholar 

  35. Cowan RJ, Chilton HM, Cooper MR, et al. (1986) Hematologic depression following therapy with strontium-89 chloride. Clin Nucl Med 11: 845–846

    PubMed  CAS  Google Scholar 

  36. Paszkowski AL, Hewitt DJ, Taylor A Jr. (1999) Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med 24: 852–854

    PubMed  CAS  Google Scholar 

  37. Bern MM. (2005) Coagulopathy, following medical therapy, for carcinoma of the prostate. Hematology 10: 65–68

    PubMed  Google Scholar 

  38. Kasalický J, Krajská V. (1998) The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med 25: 1362–1367

    PubMed  Google Scholar 

  39. Silberstein EB, Williams C. (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26: 345–348

    PubMed  CAS  Google Scholar 

  40. Mertens WC, Stitt L, Porter AT. (1993) Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship? Am J Clin Oncol 16: 238–242

    PubMed  CAS  Google Scholar 

  41. Laing AH, Ackery DM, Bayly RJ, et al. (1991) Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol 64: 816–822

    PubMed  CAS  Google Scholar 

  42. Eary JF, Collins C, Stabin M , et al. (1993) Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med 34: 1031–1036

    PubMed  CAS  Google Scholar 

  43. Alberts AS, Brighton SW, Kempff P, et al. (1995) Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget’s disease and rheumatoid arthritis. J Nucl Med 36: 1417–1420

    PubMed  CAS  Google Scholar 

  44. Menda Y, Bushnell DL, Williams RD. (2000) Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Clin. Nucl Med 25: 698–700

    PubMed  CAS  Google Scholar 

  45. Turner JH, Claringbold PG. (1991) A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 27: 1084–1086

    PubMed  CAS  Google Scholar 

  46. Maini CL, Bergomi S, Romano L, et al. (2004) 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging 31: S171–178

    PubMed  Google Scholar 

  47. Giannakenas C, Kalofonos HP, Apostolopoulos DJ, et al. (2000) Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease. Am J Clin Oncol 23: 83–88

    PubMed  CAS  Google Scholar 

  48. Kolesnikov-Gauthier H, Carpentier P, Depreux P, et al. (2000) Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer. J Nucl Med 41: 1689–1694

    PubMed  CAS  Google Scholar 

  49. Lam MG, de Klerk JM, van Rijk PP. (2004) 186Re-HEDP for metastatic bone pain in breast cancer patients. Eur J Nucl Med Mol Imaging 31: S162–S170

    PubMed  CAS  Google Scholar 

  50. Werner B, Isacson C, Lundell G, et al. (1980) 32P-pyrophosphate in the treatment of persistent metastatic bone pain. Acta Radiol Oncol 19: 327–329

    PubMed  CAS  Google Scholar 

  51. Zhang H, Tian M, Li S, et al. 2003 Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 18: 719–726

    PubMed  CAS  Google Scholar 

  52. Liepe K, Kropp J, Runge R, et al. (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89: 625–629

    PubMed  CAS  Google Scholar 

  53. Liepe K, Hliscs R, Kropp J, et al. (2003) Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 44: 953–960

    PubMed  CAS  Google Scholar 

  54. Li S, Liu J, Zhang H, et al. (2001) Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 26: 919–922

    PubMed  CAS  Google Scholar 

  55. Srivastava SC, Atkins HL, Krishnamurthy GT, et al. (1998) Treatment of metastatic bone pain with tin-117m stannic diethylenetriaminepentaacetic acid: a phase I/II clinical study. Clin Cancer Res 4: 61–68

    PubMed  CAS  Google Scholar 

  56. Turner SL, Gruenewald S, Spry N, et al. (2001) Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84: 297–302

    PubMed  CAS  Google Scholar 

  57. Windsor PM. (2001) Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre’s 10-year experience. Clin Oncol 13: 219–227

    CAS  Google Scholar 

  58. Lee CK, Aeppli DM, Unger J, et al. (1996) Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience. Am J Clin Oncol 19: 102–107

    CAS  Google Scholar 

  59. Robinson RG, Spicer JA, Preston DF, et al. (1987) Treatment of metastatic bone pain with strontium-89. Int J Rad Appl Instrum B 14: 219–222

    PubMed  CAS  Google Scholar 

  60. Giammarile F, Mognetti T, Resche I. (2001) Bone pain palliation with strontium-89 in cancer patients with bone metastases. Q J Nucl Med 45: 78–83

    Google Scholar 

  61. Li L, Liang Z, Deng H, et al. (2002) Samarium-153-EDTMP bone uptake rate and its relation to therapeutic effect. Chin Med J 115: 1096–1098

    PubMed  CAS  Google Scholar 

  62. Tian J, Cao L, Zhang J, et al. (2002) Comparative analysis of patients not responding to a single dose of 153Sm-EDTMP palliative treatment for painful skeletal metastases. Chin Med J 115: 824–828

    PubMed  Google Scholar 

  63. Robinson RG, Preston DF, Schiefelbein M, et al. (1995) Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 274: 420–424

    PubMed  CAS  Google Scholar 

  64. Sciuto R, Festa A, Pasqualoni R, et al. (2001) Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 66: 101–109

    PubMed  CAS  Google Scholar 

  65. Dearnaley DP, Bayly RJ, A’Hern RP, et al. (1992) Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89? Clin Oncol 4: 101–107

    PubMed  CAS  Google Scholar 

  66. Berna L, Carrio I, Alonso C, et al. (1995) Bone pain palliation with strontium-89 in breast cancer patients with bone metastases and refractory bone pain. Eur J Nucl Med 22: 1101–1104

    PubMed  CAS  Google Scholar 

  67. Kloiber R, Molnar CP, Barnes M, et al. (1987) Sr-89 therapy for metastatic bone disease: scintigraphic and radiographic follow-up. Radiology 163: 719–723

    PubMed  CAS  Google Scholar 

  68. Tennvall J, Darte L, Lundgren R, et al. (1988) Palliation of multiple bone metastases from prostatic carcinoma with strontium-89. Acta Oncol 27: 365–369

    PubMed  CAS  Google Scholar 

  69. Buchali K, Correns HJ, Schuerer M, et al. (1988) Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14: 349–351

    PubMed  CAS  Google Scholar 

  70. Fuster D, Herranz D, Vidal-Sicart S, et al. (2000) Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun 21: 623–626

    Google Scholar 

  71. Kovner F, Ron IG, Levita M, et al. (1993) Strontium-89 therapy in a patient with carcinoma of unknown origin and incurable pain from bone metastases. J Pain Symptom Manage 8: 47–51

    PubMed  CAS  Google Scholar 

  72. Lewington VJ, McEwan AJ, Ackery DM, et al. (1991) A prospective randomized double blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 27: 954–958

    PubMed  CAS  Google Scholar 

  73. Haesner M, Buchali K, Pink V, et al. (1992) Efficacy of Sr-89 therapy in 200 patients with skeletal metastases from prostatic carcinoma. Nucl Med 31: 48–52

    CAS  Google Scholar 

  74. Nightingale B, Brune M, Blizzard SP, et al. (1995) Strontium chloride Sr-89 for treating pain from metastatic bone disease. Am J Health Syst Pharm 52: 2189–2195

    Google Scholar 

  75. Rogers CL, Speiser BL, Ram PC, et al. (1998) Efficacy and toxicity of intravenous strontium-89 for symptomatic osseous metastasis. Brachyther Int 4: 133–142

    Google Scholar 

  76. Zorga P, Birkenfeld B. (2003) Strontium-89 in palliative treatment of painful bone metastases. Ortop Traumatol Rehabil 5: 369–73

    PubMed  Google Scholar 

  77. McEwan AJB, Porter A, Venner P, et al. (1990) An evaluation of the safety and efficacy of treatment of Sr-89 in patients who previously received wide field radiotherapy. Antibodies Immunoconj Radiopharmaceut 3: 91–98

    Google Scholar 

  78. Smeland S, Erikstein B, Aas M, et al. (2003) Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 56: 1397–1404

    PubMed  Google Scholar 

  79. Ron IG, Stav O, Vishne T, et al. (2004) The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases. Am J Clin Oncol 27: 500–504

    PubMed  Google Scholar 

  80. Mertens WC, Porter AT, Reid RH, et al. (1992) Strontium-89 and low-dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone: a preliminary report. J Nucl Med 33: 1437–1443

    PubMed  CAS  Google Scholar 

  81. Sciuto R, Maini CL, Tofani A, et al. (1996) Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 17: 799–804

    PubMed  CAS  Google Scholar 

  82. Tu SM, Millikan RE, Mengistu B, et al. (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357: 336–341

    PubMed  CAS  Google Scholar 

  83. Akerley W, Butera J, Wehbe T, et al. (2002) A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer 94: 1654–1660

    PubMed  CAS  Google Scholar 

  84. Resche I, Chatal JF, Pecking A, et al. (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33: 1583–1591

    PubMed  CAS  Google Scholar 

  85. Serafini AN. (2000) Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis. Cancer 88: 2034–2039

    Google Scholar 

  86. Serafini AN, Houston SJ, Resche I, et al. (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16: 1574–1581

    PubMed  CAS  Google Scholar 

  87. Sartor O, Reid RH, Hoskin PJ, et al. (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63: 940–945

    PubMed  Google Scholar 

  88. Turner JH, Claringbold PG, Martindale AA, et al. (1992) Samarium-153-EDTMP and radiosensitizing chemotherapy for treatment of disseminated skeletal metastasis [abstract] Eur J Nucl Med 16:S125

    Google Scholar 

  89. Liepe K, Runge R, Kotzerke J. (2005) Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 22: 457–464

    Google Scholar 

  90. Oosterhof GO, Roberts JT, de Reijke TM, et al. (2003) Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 44: 519–526

    PubMed  CAS  Google Scholar 

  91. Chow E, Danjoux C, Wong R, et al. (2000) Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists. Radiother Oncol 56: 305–314

    PubMed  CAS  Google Scholar 

  92. Hamdy NA, Papapoulos SE. (2001) The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med 31: 62–68

    PubMed  CAS  Google Scholar 

  93. Maisano R, Pergolizzi S, Cascinu S. (2001) Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol 40: 239–250

    Google Scholar 

  94. Vogel CL, Yanagihara RH, Wood AJ, et al. (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9: 687–695

    PubMed  CAS  Google Scholar 

  95. Saad F. (2002) Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin Prostate Cancer 1: 145–152

    PubMed  CAS  Google Scholar 

  96. Li EC, Davis LE. (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25: 2669–2708

    PubMed  CAS  Google Scholar 

  97. Rosen LS, Gordon D, Antonio BS, et al. (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. J Cancer 7: 377–387

    CAS  Google Scholar 

  98. Major P, Lortholary A, Hon J, et al. (2001) Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558–567

    PubMed  CAS  Google Scholar 

  99. Blake GM, Zivanovic MA, McEwan AJ, et al. (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12: 447–454

    PubMed  CAS  Google Scholar 

  100. Coleman RE. (2005) Bisphosphonates in breast cancer. Ann Oncol 16: 687–695

    PubMed  CAS  Google Scholar 

  101. Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, et al. (2002) Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging 29: 494–498

    PubMed  CAS  Google Scholar 

  102. Lam MG, Dahmane A, Stevens WH, et al. (2008) Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases. Eur J Nucl Med Mol Imaging 35: 756–765

    PubMed  CAS  Google Scholar 

  103. Blake GM, Gray JM, Zivanovic A, et al. (1987) Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol 60: 685–692

    PubMed  CAS  Google Scholar 

  104. Breen SL, Powe JE, Porter AT. (1992) Dose estimation strontium-89 radiotherapy of metastatic prostate cancer. J Nucl Med 33: 1316–1323

    PubMed  CAS  Google Scholar 

  105. Blake GM, Zivanovic MA, McEwan AJ, et al. (1987) Sr-89 radionuclide therapy: dosimetry and hematological toxicity in two patients with metastasizing prostatic carcinoma. Eur J Nucl Med 13: 41–46

    PubMed  CAS  Google Scholar 

  106. Leong C, McKenzie MR, Copland DB, et al. (1994) Disseminated intravascular coagulation in a patient with metastatic prostate cancer: total outcome following strontium-89 therapy. J Nucl Med 35: 1662–1664

    PubMed  CAS  Google Scholar 

  107. Ruffion A, Manel A, Valignant C, et al. (2000) Successful use of samarium-153 for emergency treatment of disseminated intravascular coagulation due to metastatic hormone refractory prostate cancer. J Urol 164:782

    PubMed  CAS  Google Scholar 

  108. Olea E, Riccabona G, Tian J, et al. (2000) Efficacy and toxicity of 153-Sm-EDTMP in the palliative treatment of painful skeleton metastases: results of an IAEA international multicenter study. J Nucl Med 41:146P

    Google Scholar 

  109. Sciuto R, Tofani A, Festa A, et al. (2000) Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med 41: 647–654

    PubMed  CAS  Google Scholar 

  110. Küçük NO, Ibiş E, Aras G, et al. (2000) Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases. Ann Nucl Med 14: 239–245

    PubMed  Google Scholar 

  111. Quirijnen JM, Han SH, Zonnenberg BA, et al. (1996) Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med 37: 1511–1515

    PubMed  CAS  Google Scholar 

  112. Macklis R, Lasher J. (1999) Palliative radiotherapy for skeletal metastasis: cost substitution analysis and economic impact. J Oncol Manag 8: 17–22

    Google Scholar 

  113. Malmberg I, Persson V, Ask A, et al. (1997) Painful bone metastasis in hormone refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy. Urology 50: 747–753

    PubMed  CAS  Google Scholar 

  114. McEwan AJ, Amyotte GA, McGowan DG, et al. (1994) A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone. Eur Urol 26: 26–31

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. IBB; CNR, via Pansini 5, 80131 Napoli, Italy

    Giovanni Storto

Authors
  1. Giovanni Storto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Storto .

Editor information

Editors and Affiliations

  1. Dept. of Radiation Oncology, University of Patras Medical School, 265 04, Patras, Greece

    Dimitrios Kardamakis MD, PhD, DMRT  & Vassilios Vassiliou MD, PhD  & 

  2. Dept. of Radiation Oncology, University of Toronto Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, M4N 3M5, Canada

    Edward Chow MBBS, PhD, FRCPC

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Storto, G. (2009). Radionuclide Therapy. In: Kardamakis, D., Vassiliou, V., Chow, E. (eds) Bone Metastases. Cancer Metastasis – Biology and Treatment, vol 12. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-9819-2_16

Download citation

Publish with us

Policies and ethics

Search

Navigation